Breakout Ventures Bets Big on AI Biotech

With Fund III, Breakout Ventures is doubling down on its focus: seed-stage startups that merge AI with biology, chemistry, and other sciences. They're looking for founders who can translate breakthroughs from academic labs into scalable businesses. The firm sees AI as a way to accelerate scientific discovery and commercialization, not just as a chatbot or administrative tool. They believe AI can genuinely speed up how science turns into medicine, impacting areas like drug discovery, diagnostics, and neurotechnology. Breakout Ventures' earlier funds have already had some notable successes. Surf Bio, a Fund II portfolio company, was acquired by Halozyme for up to $400 million. Another company, Cytovale, developed the first FDA-approved AI-powered rapid sepsis diagnostic. The new fund is already being deployed, with investments in companies like Reach Industries and a stealth startup from the University of Chicago. These companies are focused on visual intelligence, commercial distribution of scientific innovations, and small molecule discovery, respectively.